AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00457223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation using fibrin glue
Description: After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®) in 16 eyes of 16 patients of FG group and continuous suture with nylon 10-0 in 16 eyes of 16 patients of SU group.
Study NCT00457223 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic membrane transplantation using fibrin glue
Description: After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®) in 16 eyes of 16 patients of FG group and continuous suture with nylon 10-0 in 16 eyes of 16 patients of SU group.
Study NCT02363322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A/Current Standard of Care Alone
Description: Optimized standard of care for Ebola virus infection
Study NCT00552006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. In cooperation with the therapist the clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner.
Study NCT00552006 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Academic Counseling
Description: Missing time in educational life is one major issue for formerly abducted people. The Academic Counseling (AC) intervention is an active Control condition and improves English skills and works at the same time on concentration, learning and memory abilities. The clients will gain some of the abilities and skills they might have lost or developed weaknesses in due to their abduction.~AC will be applied in eight sessions (90-120min/session) in a standardized, manualized manner.
Study NCT03130452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 30mg
Description: lansoprazole 30 mg tablet
Study NCT03130452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30mg
Description: lansoprazole 30 mg tablet
Study NCT03130452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 1.0g Tab
Description: Amoxicillin 1.0g tablet
Study NCT03130452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1.0g Tab
Description: Amoxicillin 1.0g tablet
Study NCT03130452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: Clarithromycin 500mg tablet
Study NCT00106626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin
Description: Dose escalation study starting with vorinostat (Suberoylanilide Hydroxamic Acid \[SAHA\]) capsules 200 mg b.i.d. in combination with Pemetrexed and Cisplatin (see table for Reporting Groups).
Study NCT00732199 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1) hyperventilation via noninvasive positive pressure ventilation 2) multiple trials of episodic hypoxia
Description: 1) noninvasive hyperventilation to determine apneic threshold; 2) episodic hypoxia to determine ventilatory long term facilitation
Study NCT03130452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: Clarithromycin 500mg tablet
Study NCT03130452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 500 mg
Description: Metronidazole 500 mg tablet
Study NCT03130452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg
Description: Metronidazole 500 mg tablet
Study NCT03100214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.
Study NCT03100214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions
Study NCT00732199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1) hyperventilation via noninvasive positive pressure ventilation 2) multiple trials of episodic hypoxia
Description: 1) noninvasive hyperventilation to determine apneic threshold; 2) episodic hypoxia to determine ventilatory long term facilitation
Study NCT00517673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK945237
Study NCT00517673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Placebo
Study NCT04255329 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Montessori reading roundtable
Description: Such book is written in a way to adaptate to people with cognitif and sensory impairments. Indeed, text is written in large characters and structured to not involve episodic memory. Each person read one page aloud in his turn. After the reading phase, the participants discuss the questions about their opinions and distant memories.
Study NCT03234231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-month supervised tooth brushing programme
Description: One or a few dental hygienists, who are trained to teach how to brush and provide scaling, will supervise the students to brush daily in school for three months.
Study NCT03234231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: oral health education talk
Description: It is conducted by a dentist, while written materials will be delivered to the students and their carers.
Study NCT03323671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preemptive mefenamic acid
Description: preemptive analgesia before menstrual pain
Study NCT04255329 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual reading
Description: The readen text is a normal, currently used in a everyday life support such as a journal article.
Study NCT03323671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mefenamic acid
Description: mefenamic acid given only during menstruation
Study NCT05301738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric Exercises
Description: The plyometric exercise group received a 12-week plyometric training program. Each session lasted 45 minutes and was repeated two times a week. The training was conducted in conformity with the National Strength and Conditioning Association guidelines and American Academy of Pediatrics safety standards. The plyometric exercise program consisted of ten unilateral and bilateral lower limb plyometrics in the form of hopping/bounding/jumping activities. The Iplyometric workout was proceeded by a 5-minute warm-up and ended up with a 5-minute cool-down
Study NCT05301738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: The control group received their usual physical rehabilitation program for 45 minutes, twice/week for 12 consecutive weeks. The program comprised advanced balance training, and gait training exercises, postural and flexibility exercises, strength training exercises.
Study NCT01238978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Study NCT01238978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study NCT02059954 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterectomy
Study NCT00330668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rh IGF-1 (mecasermin)
Description: Patients from untreated arm for prior study MS301 (NCT00125164) were randomized to a dose of either 80 or 120 mcg/kg twice daily. For patients receiving active treatment in previous study MS 301 (NCT00125164), they started on a dose of 80 or 120 mcg/kg twice daily based on the dose reached at end of the previous study. Following a protocol amendment in May 2009, all patients were switched to once daily doses of 160 µg/kg, escalated to a targeted maximum dose of 240 µg/kg.
Study NCT01096810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBL 12
Description: TBL 12 will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression.
Study NCT01819454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pH monitoring (Restech)
Description: see in detail description of the study part of the protocol
Study NCT00509782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIO-101
Description: Starting Dose 78 mg/m\^2 intravenously daily for 5 consecutive days repeated every 4 weeks.
Study NCT00917709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging with IBVM
Description: in vivo molecular imaging of presynaptic molecular target of cholinergic systems with \[123I\]-iodobenzovesamicol
Study NCT00917709 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Imaging with IBVM
Description: in vivo molecular imaging of presynaptic molecular target of cholinergic systems with \[123I\]-iodobenzovesamicol
Study NCT00917709 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Imaging with IBVM
Description: in vivo molecular imaging of presynaptic molecular target of cholinergic systems with \[123I\]-iodobenzovesamicol
Study NCT00917709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging with DATSCAN
Description: in vivo molecular imaging of presynaptic molecular target of dopaminergic systems (DAT) with DATSCAN
Study NCT00917709 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Imaging with DATSCAN
Description: in vivo molecular imaging of presynaptic molecular target of dopaminergic systems (DAT) with DATSCAN
Study NCT00086489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: pts treated at 10 mg/kg dose level on a monthly regimen
Study NCT00086489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: pts treated at 15 mg/kg dose level on a quarterly regimen
Study NCT02424890 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MDT simulation sessions of management of life-threatening events over 1 year
Description: 9 simulation sessions over 1 year for Repetitive Sim Group and 3 simulation sessions over 1 year for Control Group
Study NCT02359500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATOC PET
Description: 68Ga-DOTATOC as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors.
Study NCT01404884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SUPRACOR
Description: The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. In addition to the treatment for the distance vision an additional central ablation component will be added to address the near vision.
Study NCT03524664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuning In to kids intervention
Description: The Tuning Into Kids Program involves:~* Meeting in a small group with other caregivers raising children with FASD.~* 8-week program that meets weekly for 2 hours at Mt. Hope Family Center or other community location.~* Learn and practice an approach of responding to children's emotions and behavior.
Study NCT01288742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: One 10-mg tablet for 1 day (Trt C).
Study NCT01288742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
Study NCT01288742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: One 150-mg capsule once daily for 7 days (Trts B and D).
Study NCT01288742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
Study NCT01288742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: One 0.25-mg tablet for 1 day (Trt A)
Study NCT04865016 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis +2.75 D (ZKB00) and Tecnis Symfony (ZXR00)
Description: This study included 30 eyes of 15 cataract patients undergoing cataract surgery with implantation of a low add (+2.75 Diopters \[D\]) bifocal (Tecnis ZKB00; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (MIOL Group) and 30 eyes of 15 patients with implantation of an EDOF (Tecnis Symfony \[ZXR00\]; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (EDOF Group).
Study NCT02495714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active learning
Description: Physical activity one hour a day as part of academic learning
Study NCT00917709 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Imaging with DATSCAN
Description: in vivo molecular imaging of presynaptic molecular target of dopaminergic systems (DAT) with DATSCAN
Study NCT00917709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological evaluation
Description: neuropsychological evaluation using neuropsychological tests
Study NCT00917709 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: neuropsychological evaluation
Description: neuropsychological evaluation using neuropsychological tests
Study NCT00917709 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: neuropsychological evaluation
Description: neuropsychological evaluation using neuropsychological tests
Study NCT02914652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Ventoline(R), inhalation spray, 0,1 mg/dose, 9 doses administered as coherent single doses.
Study NCT01013779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: During radiotherapy: Carboplatin (AUC2) commences on day 1 of radiation and is repeated at weekly intervals on days 8, 15, 22 and 29 (of radiation).~After radiotherapy: 3 weeks after completing radiotherapy, 3 cycles of 3 weekly carboplatin (AUC4.5) intravenously on day 1.
Study NCT01013779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: After Radiotherapy: 3 weeks after completing the radiation therapy, 3 cycles of 3 weekly etoposide (80mg/M2/day) intravenously days 1-3
Study NCT01013779 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Microscopic Disease: 50Gy delivered in 2Gy doses over 25 fractions~Macroscopic Disease: 54Gy delivered in 2Gy doses over 27 fractions
Study NCT01839656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection
Study NCT01295684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Description: base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day
Study NCT01295684 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage
Study NCT03705975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual treatment
Description: Scapula mobilization, glenohumeral joint mobilization
Study NCT01713556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Study NCT01713556 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Trauma reactivation
Description: Trauma reactivation: script-driven mental imagery of the traumatic event
Study NCT01713556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trauma reactivation
Description: Trauma reactivation: script-driven mental imagery of the traumatic event
Study NCT01713556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03300297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Spine Thrust Joint Manipulation
Description: High velocity, short amplitude thrust to the cervical spine
Study NCT03300297 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cervical Spine Sham Manipulation
Description: Manipulative hold position shy of end range without a thrust
Study NCT02914652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norflouran (Placebo Evohaler(R) )
Description: Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.
Study NCT04407312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol Tablets
Description: Cilostazol-SR, capsule, 200mg, once daily, 30 days.
Study NCT04407312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo, tablet, 200mg, once daily, 30 days.
Study NCT04407312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Astrix, capsule,100mg, once daily, 30 days.
Study NCT04407312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Astrix, capsule,100mg, once daily, 30 days.
Study NCT04407312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Plavix, tablet, 75mg, once daily, 30 days.
Study NCT03300297 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Home Program
Description: therapeutic exercise program and education
Study NCT03300297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Program
Description: therapeutic exercise program and education
Study NCT03300297 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Suboccipital Release
Description: suboccipital soft tissue mobilization
Study NCT03300297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suboccipital Release
Description: suboccipital soft tissue mobilization
Study NCT04407312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: Plavix, tablet, 75mg, once daily, 30 days.
Study NCT04120974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimal insulin injection
Description: subjects receive training in optimal injection technique.
Study NCT00881933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyclophosphosphamide, TBI
Description: fludarabine (30 mg/m2 once daily i.v. on days -7, -6, -5, -4, -3, \& -2) (if body weight \< 10 kg or if age \< 1 year: 1.33 mg/kg) cyclophosphamide (60 mg/kg once daily i.v. on days -9, \& -8) total body irradiation (3G on days -1)
Study NCT03089606 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDG PET/CT scan
Description: 18F-fluorodeoxy glucose (FDG) positron emission tomography (PET) with intravenous (IV) contrast images are obtained before and at the end study treatment (pembrolizumab infusion).
Study NCT03089606 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: C11-AMT PET scan
Description: 11C-methyl-L-tryptophan (C11-AMT) positron emission tomography (PET) images are obtained before study treatment (pembrolizumab infusion).
Study NCT03089606 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: 200 mg Pembrolizumab IV administered over 30 minutes on day 1. Repeat every 3 weeks for 4 cycles, until progression, or subject withdrawal for other reasons
Study NCT03089606 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT scan
Description: Computerized tomography (CT) images are taken without IV contrast before the treatment (pembrolizumab infusion) and with IV contrast 3 months after the treatment start.
Study NCT01482247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginine
Description: Dietary Supplement
Study NCT01482247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplement
Description: Dietary Supplement
Study NCT01980355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT01980355 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06473259 — intervention group
Intervention type: DRUG
Intervention: Docetaxel
Description: 6 courses of docetaxel 75 mg/sqm iv
Study NCT06473259 — intervention group
Intervention type: DRUG
Intervention: Apalutamide Oral Tablet
Description: 240 mg /daily orally
Study NCT06473259 — intervention group
Intervention type: DRUG
Intervention: Enzalutamide Oral Tablet
Description: 600 mg /daily orally
Study NCT06473259 — intervention group
Intervention type: DRUG
Intervention: Abiraterone acetate tablets
Description: 1000 mg /daily orally
Study NCT02495714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary councelling
Description: Teaching children and parents about a healthy diet